MARKET

ITCI

ITCI

INTRA CELLULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.27
+0.46
+2.91%
Opening 10:32 03/31 EDT
OPEN
15.80
PREV CLOSE
15.81
HIGH
16.34
LOW
15.67
VOLUME
93.91K
TURNOVER
--
52 WEEK HIGH
43.56
52 WEEK LOW
6.75
MARKET CAP
1.08B
P/E (TTM)
-6.0784
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ITCI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ITCI stock price target is 46.00 with a high estimate of 70.00 and a low estimate of 35.00.

EPS

ITCI News

More
  • Intra-Cellular Therapies (ITCI): Strong Industry, Solid Earnings Estimate Revisions
  • Zacks · 4d ago
  • Intra-Cellular Therapies Announces Availability of CAPLYTA (lumateperone) for Adult Patients with Schizophrenia
  • GlobeNewswire · 03/23 12:30
  • 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades
  • Benzinga · 03/17 21:21
  • Alkermes: Lack Of Near-Term Catalysts
  • Seeking Alpha - Article · 03/13 18:54

Industry

Biotechnology & Medical Research
-0.03%
Pharmaceuticals & Medical Research
-0.15%

Hot Stocks

Symbol
Price
%Change

About ITCI

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).
More

Webull offers kinds of Intra-Cellular Therapies Inc stock information, including NASDAQ:ITCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITCI stock news, and many more online research tools to help you make informed decisions.